Topics

STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

08:33 EDT 28 Oct 2019 | STAT

California biotech Nuvation announced itself to the world on Monday with $275 million — one of the largest Series A funding rounds in 2019 — and a familiar name as…

Original Article: STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...